Literature DB >> 19129449

An HLA-A2-restricted T-cell epitope mapped to the BNLF2a immune evasion protein of Epstein-Barr virus that inhibits TAP.

Melissa J Bell1, Rachel J M Abbott, Nathan P Croft, Andrew D Hislop, Scott R Burrows.   

Abstract

The early lytic cycle protein of Epstein-Barr virus (EBV), BNLF2a, has recently been shown to play a critical role in immune evasion by inhibiting the peptide transporter associated with antigen processing (TAP), thereby blocking antigen-specific CD8(+) T-cell recognition of many lytic cycle antigens. Surprisingly, we now show that a peptide ((50)VLFGLLCLL(58)) from the hydrophobic C-terminal region of this small (60-amino-acid) EBV protein is efficiently presented by the common class I allele HLA-A2 for recognition by cytotoxic T lymphocytes. The mechanism for this unexpected finding was revealed by experiments showing that this epitope is processed and presented independently of TAP.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19129449      PMCID: PMC2648255          DOI: 10.1128/JVI.01724-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  23 in total

1.  A-type and B-type Epstein-Barr virus differ in their ability to spontaneously enter the lytic cycle.

Authors:  M Buck; S Cross; K Krauer; N Kienzle; T B Sculley
Journal:  J Gen Virol       Date:  1999-02       Impact factor: 3.891

2.  Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules.

Authors:  K Falk; O Rötzschke; S Stevanović; G Jung; H G Rammensee
Journal:  Nature       Date:  1991-05-23       Impact factor: 49.962

3.  The human cytomegalovirus US6 glycoprotein inhibits transporter associated with antigen processing-dependent peptide translocation.

Authors:  P J Lehner; J T Karttunen; G W Wilkinson; P Cresswell
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-24       Impact factor: 11.205

4.  The ER-luminal domain of the HCMV glycoprotein US6 inhibits peptide translocation by TAP.

Authors:  K Ahn; A Gruhler; B Galocha; T R Jones; E J Wiertz; H L Ploegh; P A Peterson; Y Yang; K Früh
Journal:  Immunity       Date:  1997-05       Impact factor: 31.745

5.  A viral ER-resident glycoprotein inactivates the MHC-encoded peptide transporter.

Authors:  H Hengel; J O Koopmann; T Flohr; W Muranyi; E Goulmy; G J Hämmerling; U H Koszinowski; F Momburg
Journal:  Immunity       Date:  1997-05       Impact factor: 31.745

Review 6.  Mechanisms of MHC class I--restricted antigen processing.

Authors:  E Pamer; P Cresswell
Journal:  Annu Rev Immunol       Date:  1998       Impact factor: 28.527

7.  Human herpes simplex virus (HSV)-specific CD8+ CTL clones recognize HSV-2-infected fibroblasts after treatment with IFN-gamma or when virion host shutoff functions are disabled.

Authors:  M A Tigges; S Leng; D C Johnson; R L Burke
Journal:  J Immunol       Date:  1996-05-15       Impact factor: 5.422

8.  A viral inhibitor of peptide transporters for antigen presentation.

Authors:  K Früh; K Ahn; H Djaballah; P Sempé; P M van Endert; R Tampé; P A Peterson; Y Yang
Journal:  Nature       Date:  1995-06-01       Impact factor: 49.962

9.  Transfer and expression of three cloned human non-HLA-A,B,C class I major histocompatibility complex genes in mutant lymphoblastoid cells.

Authors:  Y Shimizu; D E Geraghty; B H Koller; H T Orr; R DeMars
Journal:  Proc Natl Acad Sci U S A       Date:  1988-01       Impact factor: 11.205

10.  T cell receptor repertoire for a viral epitope in humans is diversified by tolerance to a background major histocompatibility complex antigen.

Authors:  S R Burrows; S L Silins; D J Moss; R Khanna; I S Misko; V P Argaet
Journal:  J Exp Med       Date:  1995-12-01       Impact factor: 14.307

View more
  7 in total

1.  Latent Expression of the Epstein-Barr Virus (EBV)-Encoded Major Histocompatibility Complex Class I TAP Inhibitor, BNLF2a, in EBV-Positive Gastric Carcinomas.

Authors:  Michael J Strong; Thomas Laskow; Hani Nakhoul; Eugene Blanchard; Yaozhong Liu; Xia Wang; Melody Baddoo; Zhen Lin; Qinyan Yin; Erik K Flemington
Journal:  J Virol       Date:  2015-07-15       Impact factor: 5.103

Review 2.  Generation of MHC class I ligands in the secretory and vesicular pathways.

Authors:  Margarita Del Val; Salvador Iborra; Manuel Ramos; Silvia Lázaro
Journal:  Cell Mol Life Sci       Date:  2011-03-09       Impact factor: 9.261

3.  Contribution of susceptibility locus at HLA class I region and environmental factors to occurrence of nasopharyngeal cancer in Northeast India.

Authors:  Meena Lakhanpal; Laishram Chandreshwor Singh; Tashnin Rahman; Jagnnath Sharma; M Madhumangal Singh; Amal Chandra Kataki; Saurabh Verma; Pradeep Singh Chauhan; Y Mohan Singh; Saima Wajid; Sujala Kapur; Sunita Saxena
Journal:  Tumour Biol       Date:  2014-12-17

4.  HLA associations in classical Hodgkin lymphoma: EBV status matters.

Authors:  Xin Huang; Kushi Kushekhar; Ilja Nolte; Wierd Kooistra; Lydia Visser; Ilby Bouwman; Niels Kouprie; Rianne Veenstra; Gustaaf van Imhoff; Bianca Olver; Richard S Houlston; Sibrand Poppema; Arjan Diepstra; Bouke Hepkema; Anke van den Berg
Journal:  PLoS One       Date:  2012-07-10       Impact factor: 3.240

5.  Detection of Epstein-Barr Virus Infection in Non-Small Cell Lung Cancer.

Authors:  Fayez Kheir; Mengmeng Zhao; Michael J Strong; Yi Yu; Asuka Nanbo; Erik K Flemington; Gilbert F Morris; Krzysztof Reiss; Li Li; Zhen Lin
Journal:  Cancers (Basel)       Date:  2019-05-31       Impact factor: 6.639

Review 6.  Pathogenic Role of Epstein-Barr Virus in Lung Cancers.

Authors:  David Becnel; Ramsy Abdelghani; Asuka Nanbo; Janardhan Avilala; Jacob Kahn; Li Li; Zhen Lin
Journal:  Viruses       Date:  2021-05-11       Impact factor: 5.048

7.  Mechanism of activation of the BNLF2a immune evasion gene of Epstein-Barr virus by Zta.

Authors:  Rajaei Almohammed; Kay Osborn; Sharada Ramasubramanyan; Ijiel Barak Naranjo Perez-Fernandez; Anja Godfrey; Erika J Mancini; Alison J Sinclair
Journal:  J Gen Virol       Date:  2018-03-26       Impact factor: 3.891

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.